Clinical Trial Update: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing the safety, tolerability, and efficacy of NVG-2089 in participants with chronic inflammatory demyelinating polyneuropathy (CI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• NVG-2089

Snippet

Sponsor: Nuvig Therapeutics, Inc. | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Status: ACTIVE_NOT_RECRUITING